We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Prestige Consumer Healthcare (PBH) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Prestige Consumer Healthcare (PBH - Free Report) to post quarterly earnings of $1.44 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $294.29 million, down 0.8% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Prestige Consumer Healthcare metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- OTC Healthcare- International' at $47.65 million. The estimate indicates a change of +0.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- OTC Healthcare- North American' should come in at $245.89 million. The estimate points to a change of -1.2% from the year-ago quarter.
Analysts' assessment points toward 'Gross profit- OTC Healthcare- North American' reaching $142.40 million. The estimate compares to the year-ago value of $141.49 million.
Analysts expect 'Gross profit- OTC Healthcare- International' to come in at $27.92 million. The estimate is in contrast to the year-ago figure of $28.52 million.
Over the past month, shares of Prestige Consumer Healthcare have returned -3.8% versus the Zacks S&P 500 composite's +11% change. Currently, PBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Prestige Consumer Healthcare (PBH) Q4 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Prestige Consumer Healthcare (PBH - Free Report) to post quarterly earnings of $1.44 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $294.29 million, down 0.8% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Prestige Consumer Healthcare metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- OTC Healthcare- International' at $47.65 million. The estimate indicates a change of +0.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- OTC Healthcare- North American' should come in at $245.89 million. The estimate points to a change of -1.2% from the year-ago quarter.
Analysts' assessment points toward 'Gross profit- OTC Healthcare- North American' reaching $142.40 million. The estimate compares to the year-ago value of $141.49 million.
Analysts expect 'Gross profit- OTC Healthcare- International' to come in at $27.92 million. The estimate is in contrast to the year-ago figure of $28.52 million.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>Over the past month, shares of Prestige Consumer Healthcare have returned -3.8% versus the Zacks S&P 500 composite's +11% change. Currently, PBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .